Sugi Predict

Sugi Predict / Compounds / SCHEMBL16039634

SCHEMBL16039634

SCHEMBL16039634

CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1.O=P(O)(Oc1ccccc1)Oc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.61
▸ MEN1 O00255 4/20 0.61
▸ KMT2A Q03164 4/20 0.61
▸ MAPT P10636 2/20 0.61
▸ ALOX15 P16050 1/20 0.61
▸ LMNA P02545 1/20 0.45
▸ CACNA1D Q01668 3/20 0.43
▸ ADORA3 P0DMS8 3/20 0.42
▸ ALDH1A1 P00352 5/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ XBP1 P17861 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ DHFR P00374 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ AGTR1 P30556 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95164 0.78 KDM4E (1.00) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL8037231 0.76 KDM4E (0.86) KDM4EMEN1KMT2AMAPTALOX15
Acetic Acid SCHEMBL28855875 0.74 KDM4E (0.83) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL11262327 0.74 KMT2A (0.60) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL14957474 0.73 KDM4E (0.80) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL17367952 0.73 KDM4E (0.86) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL30987784 0.73 KDM4E (0.86) KDM4EMEN1KMT2AMAPTALOX15
Ether SCHEMBL574793 0.72 SRC (0.55) LMNAALDH1A1L3MBTL1
Butane SCHEMBL924011 0.72 SRC (0.59) MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL10984281 0.72 MEN1 (0.61) KDM4EMEN1KMT2AMAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11498926-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE CORPORATION (US) 2022-11-15 — — US disclosed
EP-3581576-B1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR INCYTE HOLDINGS CORP (US) 2022-01-26 — — EP disclosed
US-20210188872-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORTION 2021-06-24 — — US disclosed
US-10919912-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE HOLDINGS CORPORATION (US) 2021-02-16 — — US disclosed
US-20200131195-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION 2020-04-30 — — US disclosed
US-10464947-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE HOLDINGS CORPORATION (US) 2019-11-05 — — US disclosed
EP-2970282-B1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE HOLDINGS CORP (US) 2019-08-21 — — EP disclosed
US-20180346481-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION 2018-12-06 — — US disclosed
US-9938294-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE CORPORATION (US) 2018-04-10 — — US disclosed
US-20170210754-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE HOLDINGS CORPORATION (US) 2017-07-27 — — US disclosed
US-9624241-B2 Tricyclic heterocycles as BET protein inhibitors INCYTE CORPORATION (US) 2017-04-18 — — US disclosed
US-20160046650-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2016-02-18 — — US disclosed
EP-2970282-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS Incyte Corporation (US) 2016-01-20 — — EP disclosed
US-9227985-B2 Tricyclic heterocycles as bet protein inhibitors INCYTE CORPORATION (US) 2016-01-05 — — US disclosed
US-20140275030-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2014-09-18 — — US disclosed
WO-2014143768-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275030-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 KDM4E 1807/4885MEN1 2156/4885KMT2A 742/4885
US-20160046650-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 KDM4E 1807/4885MEN1 2156/4885KMT2A 742/4885
US-20200131195-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 KDM4E 1447/4885MEN1 1742/4885KMT2A 650/4885
US-20210188872-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 KDM4E 1447/4885MEN1 1742/4885KMT2A 650/4885
US-20170210754-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 KDM4E 1807/4885MEN1 2156/4885KMT2A 742/4885
US-11498926-B2 Tricyclic heterocycles as BET protein inhibitors BRD1, BRD3, BRD2 KDM4E 1447/4885MEN1 1742/4885KMT2A 650/4885
US-10464947-B2 Tricyclic heterocycles as BET protein inhibitors BRD1, BRD3, BRD2 KDM4E 1447/4885MEN1 1742/4885KMT2A 650/4885
US-20180346481-A1 TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 KDM4E 1447/4885MEN1 1742/4885KMT2A 650/4885
US-10919912-B2 Tricyclic heterocycles as BET protein inhibitors BRD1, BRD3, BRD2 KDM4E 1447/4885MEN1 1742/4885KMT2A 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.